Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FasTCAR Dual-targeting (AML)
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GC506 is an investigational, autologous, dual-targeting chimeric antigen receptor T-cell (CAR-T) therapy developed by Gracell Biopharma (now a subsidiary of AstraZeneca) for the treatment of relapsed or refractory acute myeloid leukemia (AML). It is built on the proprietary FasTCAR platform, which enables next-day manufacturing (22-36 hours), significantly reducing the "vein-to-vein" time compared to traditional CAR-T processes. GC506 is engineered to simultaneously target two myeloid-associated antigens, CD33 and CLL-1 (CLEC12A), to address the clonal heterogeneity of AML and minimize the risk of immune escape. The therapy is currently being evaluated in investigator-initiated trials (IIT) to assess its safety and preliminary efficacy.
- Other names
- FasTCAR Dual-targetingCD33/CLL-1 FasTCAR
Beyond the preview
Go deeper on FasTCAR Dual-targeting (AML).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FasTCAR Dual-targeting (AML).